Shots:

• The collaboration will evaluate Nektar Therapeutics’ bempegaldesleukin in combination with BMS’ Opdivo (nivolumab) into multiple new registrational trials and the cost of trials will be shared upon the cost-sharing outlined in the terms of the original collaboration agreement
• The companies have expanded their collaboration for bempeg + nivolumab from three ongoing registrational trials targeted for 1L metastatic melanoma- 1L cisplatin-ineligible metastatic urothelial cancer- 1L metastatic RCC to two additional trials for adjuvant melanoma & in muscle-invasive bladder cancer
• Additionally- BMS to initiate and fund the P-I/II dose optimization and expansion study for bempeg + nivolumab in combination with axitinib to treat 1L RCC. Bempeg is a CD122-preferential IL-2 pathway agonist targeted for rapid activation and proliferation of cancer-killing immune cells

Click here to read full press release/ article | Ref: BMS | Image: Behance